metaPreg - Topiramate (Epilepsy) during pregnancy

Topiramate (Epilepsy)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.06 [1.34, 3.17]	0%	9 studies	229	323	not evaluable	ROB	3.54 [2.01; .]
Major congenital malformations	2.06 [1.34, 3.17]	0%	9 studies	229	323	not evaluable	ROB	3.54 [2.01; .]
Congenital heart defects	2.75 [0.99, 7.59]	0%	4 studies	32	233	not evaluable	ROB	-
Limb defects	3.56 [0.59, 21.68]	0%	3 studies	5	81	not evaluable	ROB	-
Neural Tube Defects	5.56 [0.78, 39.78]	0%	3 studies	2	224	not evaluable	ROB	-
Digestive system anomalies	6.26 [0.69, 56.84]	0%	2 studies	4	37	not evaluable	ROB	-
Urinary malformations	1.68 [0.22, 13.11]	0%	2 studies	14	161	not evaluable	ROB	-
Hypospadias	3.30 [0.73, 14.97]	0%	2 studies	14	180	not evaluable	ROB	-
Oro-facial clefts	7.95 [0.83, 76.53]	19%	2 studies	5	180	not evaluable	ROB	-
4 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Small for gestational age (weight)	1.79 [1.19, 2.72]	62%	3 studies	41,644	611	not evaluable	ROB	2.99 [1.66; .]
Preterm (< 37 weeks)	0.75 [0.49, 1.16]	0%	2 studies	160,598	2	not evaluable	ROB	-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
2 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Emotional disorders	0.92 [0.43, 1.97]	48%	2 studies	466	317	not evaluable	ROB	-
1 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Intrauterine deaths (as a whole or unspecified)	9.39 [2.18, 40.53]	7%	4 studies	14	70	not evaluable	ROB	18.26 [3.77; .]
Late intrauterine deaths (> 22 weeks)	15.37 [0.63, 376.77]	0%	2 studies		3	not evaluable	ROB	-
Early intrauterine death (< 22 weeks)	8.47 [0.57, 125.19]	0%	2 studies	3	4	not evaluable	ROB	-
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
ASD (Autism spectrum disorder): Diagnosis/Risk	2.00 [1.02, 3.91]	0%	3 studies	359	297	not evaluable	ROB	3.41 [1.18; .]
Language disorders/delay	1.76 [0.63, 4.86]	0%	3 studies	43	36	not evaluable	ROB	-
ASD (Autism spectrum disorder): Risk	2.65 [0.36, 19.38]	0%	2 studies	28	7	not evaluable	ROB	-
Neuro-developmental disorders (as a whole)	2.15 [1.15, 4.01]	0%	2 studies	455	248	not evaluable	ROB	3.72 [1.57; .]
ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk	1.64 [0.71, 3.81]	66%	2 studies	544	317	not evaluable	ROB	-
ASD (Autism spectrum disorder): Diagnosis	2.02 [1.00, 4.08]	0%	2 studies	331	291	not evaluable	ROB	-
Cognitive developmental disorders/delay (> 6 years old)	2.22 [1.00, 4.91]	0%	2 studies	195	317	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Diagnosis	2.38 [1.40, 4.05]	-	1 study	544	290	not evaluable	ROB	4.19 [2.14; .]
2 non statistically significant endpoints reported in only one study